There are currently 17 ongoing clinical trials involving Tourette Syndrome
Of the 17 trials,7 trials are in Phase II
Furthermore, 4 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Tourette Syndrome, a Central Nervous System condition. The largest number of ongoing clinical trials for Tourette Syndrome is conducted in the Asia-Pacific region. North America, Europe and South and Central America are among some of the other prominent regions engaged in Tourette Syndrome-related drug trials.
China Medical University Hospital and Vickmans Laboratories Ltd : The leading ongoing Tourette Syndrome related clinical trial sponsors
China Medical University Hospital and Vickmans Laboratories Ltd are the top sponsors for Tourette Syndrome-related ongoing clinical trials.
The General Hospital of the People's Liberation Army, Tianjin Zhongxin Pharmaceutical Group Corp Ltd, NYU Langone Health System and Nanjing Medical University Hospital 2 are among other notable clinical trial sponsors involved in Tourette Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Tourette Syndrome
Aripiprazole (Abilify), Tetrabenazine (Xenazine) and Haloperidol (Haloperidol Decanoate) are among the key marketed drugs involving Tourette Syndrome.
Aripiprazole (Abilify) is an antipsychotic agent. It functions via 5-Hydroxytryptamine Receptor 1A Agonist; 5-Hydroxytryptamine Receptor 2A Antagonist; D2 Dopamine Receptor Agonist mechanism of action. Aripiprazole is formulated as tablets and solution for oral route of administration and injection solution for intramuscular route of administration. Aripiprazole was first approved in 2002 and is marketed globally in the US, UK, China, Japan, France and Germany by several prominent pharma giants including Otsuka America Pharmaceutical Inc.
Tetrabenazine (Xenazine) is an isoquinoline derivative acts as antidyskinetic agent. It functions via Synaptic Vesicular Amine Transporter Inhibitor mechanism of action. Tetrabenazine is formulated as tablets for oral route of administration. Tetrabenazine was first approved in 1969 and is marketed globally in the US, UK, China, Japan, France and Germany by several prominent pharma giants including Bausch & Lomb Pharmaceuticals Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer